Tamarack Advisers, LP Iveric Bio, Inc. Transaction History

Tamarack Advisers, LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $1.41 Million - $2.79 Million	-150,000 Reduced 75.0%	50,000 $897,000
Q2 2022 Aug 16, 2022	SELL	$9.12 - $18.9 $1.55 Million - $3.21 Million	-170,000 Reduced 45.95%	200,000 $1.92 Million
Q1 2022 May 11, 2022	BUY	$12.15 - $16.83 $1.76 Million - $2.44 Million	145,000 Added 64.44%	370,000 $6.23 Million
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $345,750 - $469,500	-25,000 Reduced 10.0%	225,000 $3.76 Million
Q3 2021 Nov 12, 2021	SELL	$7.07 - $17.5 $1.06 Million - $2.63 Million	-150,000 Reduced 37.5%	250,000 $4.06 Million

Q2 2021 Aug 13, 2021	SELL	$5.69 - $7.17 $995,750 - $1.25 Million	-175,000 Reduced 30.43%	400,000 $2.52 Million
Q1 2021 May 12, 2021	SELL	$5.08 - $6.89 $1.4 Million - $1.89 Million	-275,000 Reduced 32.35%	575,000 $3.55 Million
Q4 2020 Feb 10, 2021	SELL	$5.65 - $7.66 $282,500 - $383,000	-50,000 Reduced 5.56%	850,000 $5.81 Million
Q3 2020 Nov 12, 2020	SELL	$4.01 - $6.29 $401,000 - $629,000	-100,000 Reduced 10.0%	900,000 $5.08 Million
Q2 2020 Aug 11, 2020	SELL	$3.06 - $6.6 $765,000 - $1.65 Million	-250,000 Reduced 20.0%	1,000,000 $5.1 Million
Q1 2020 May 14, 2020	SELL	$2.83 - $8.44 $3.96 Million - $11.8 Million	-1,400,000 Reduced 52.83%	1,250,000 $4.3 Million
Q4 2019 Feb 11, 2020	SELL	$0.93 - $8.58 $325,500 - $3 Million	-350,000 Reduced 11.67%	2,650,000 $21.6 Million
Q2 2019 Aug 12, 2019	BUY	$1.21 - $1.48 $3.63 Million - $4.44 Million	3,000,000 New	3,000,000 $3.72 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Tamarack Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Tamarack Advisers, LP with notifications on news.